FDA Advisors Give PTSD Drug Combination a Thumbs Down

(MedPage Today) -- FDA's outside experts weren't sold on the trial data for brexpiprazole (Rexulti) as an adjunctive treatment for post-traumatic stress disorder (PTSD), sinking its prospects for approval in this setting.
In a 10-1 vote on Friday...